QLS5132 / Qilu Pharma - LARVOL DELTA

QLS5132, a highly selective anti-CLDN6 ADC with broader therapeutic window (AACR 2025) - "QLS5132 showed an expanded therapeutic window with superior efficacy and tolerability to TORL-1-23 in preclinical models. QLS5132 also demonstrated great potential to combine with PARPi in CLDN6 positive ovarian cancers. QLS5132 is expected to offer a novel and promising treatment option either as a single agent or combo with PARPi or other SoCs for patients with CLDN6 expressing tumors."

Endometrial Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer • CLDN6

Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=256 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

Monotherapy • New P1 trial • Solid Tumor